Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Jacques Chitte who wrote (2841)	3/19/1998 1:30:00 PM
From: F. Jay Abella, III	Read Replies (1) \| Respond to of 7041

Dauntless: I commend you for being truly as your screen name suggests. Two interpretations of today's event; 1) Positive spin - Mexican filing is a precursor for other filings around the world. Earnings will come from sales of Vasomax upon an approval. Phase IV safety and efficacy data can be generated, etc. 2) Cynical view - SGP was brought in to have an "all hands on deck" team for a US NDA filing, preferably before a decision on Viagra was made. This was the basis on which most, if not all, of the potential $57mm deal was negotiated (correct me if there is a milestone payment for a Mexican approval). Without such incentive, it is curious that the ZONA/SGP team made Mexico its first priority. Why? We'll let the cynics address this one. You don't think there is maybe a little room for skepticism here? The market is presently leaning toward a thumbs down. However, throw in a stock buy back, a recipe for how a short squeeze could be orchestrated, a pile of shareholder lawsuits and Mexican approval as job #1 for SGP and no longer does ZONA take the form of the run-of-the-mill late-stage hit-or-miss biotech. Can't wait to read the 10-K FJA